Wells Messersmith, MD Visiting Associate Professor Williams College (Williamstown, MA), BA 1992 Harvard Medical School (Boston, MA), MD 1998 University of Colorado Denver School of Medicine Division of Medical Oncology Tel: (303) 724-0747 Fax: (303) 724-3892 e-mail: wells.messersmith@uchsc.edu Bio Dr. Messersmith joined the UCDHSC faculty in August 2007 as the Director of Gastrointestinal Medical Oncology as well as an active participant in the Drug Development Program.  He trained in internal medicine at Massachusetts General Hospital / Harvard Medical School and did his Medical Oncology / Drug Development Fellowship at Johns Hopkins, where he was on the faculty from 2004-2007 as Assistant Professor in the GI Oncology and Drug Development programs. Research Dr. Messersmith is focused on clinical and translational cancer research and is the director of the Gastrointestinal (GI) Medical Oncology Program. This comprehensive program includes multi-disciplinary GI cancer clinics, tumor boards, and research endeavors. Dr. Messersmith holds several NIH grants (K23, R21) and is the principal investigator on numerous national and local therapeutic trials.  He is an active investigator in the developmental therapeutics laboratory, working on novel targeted therapies as well as correlative studies for use on human tissue samples.

FACULTY LIST Lynn Bemis Virginia Borges Paul Bunn David Calverley Ross Camidge Dan Chan Gail Eckhardt Anthony Elias Thomas Flaig Marileila Garcia L. Michael Glode Rene Gonzalez Barb Helfrich Fred Hirsch Christopher Hogan Antonio Jimeno Madeleine Kane Choon-Kee Lee Stephen Leong Wells Messersmith Han Myint Ana Oton Peter Raich William Robinson Pepper Schedin John Tentler William Tse Colin Weekes

Publications
Messersmith WA, Laheru DL, Senzer N, Donehower RC, Grouleff P, Kelley S, and Hidalgo M, Phase 1trial of irinotecan, infusionaI5-FU, and leucovorin (FOLFIRI) with erlotinib (OSI-774): early termination due to increased toxicities. Clinical Cancer Research 2004; I0:6522-6527.

Messersmith W, Oppenheimer 0, Peralba J, Sebastiani V, Amador M, Jimeno A, Embuscado E, Hidalgo M, lacobuzio-Donahue C, Assessment of epidermal growth factor receptor (EGFR)
signaling in paired colorectal cancer and normal colon tissue samples using computer-aided
immunohistochemical analysis. Cancer Biology and Therapy 2005;4(12): 1381 – 1386.

Messersmith WA, Baker SO, Lassiter L, Sullivan RA, Oinh K, Almuete VI, Wright JJ,
Oonehower RC, Carducci MA, and Almstrong OK, Phase I trial of bortezomib in combination
with docetaxel in patients with advanced solid tumors. Clinical Cancer Research 2006: 12: 1270-75.

Funding
K23CA115500: Evaluation of Oral EGFR Inhibitors in Colorectal Cancer    
R21CA117125: Evaluation of BAY43-9006/Cetuximab in Colorectal Cancer
NCCN Clinical Trials Network
ASCO Young Investigator Award

PubMed articles

BACK TO TOP